# US 2006/0051355 A1 · Methods and means for the treatment of immune-related diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0051355 A1
- Document ID: US20060051355A1
- Status: Published application
- Kind: A1
- Application number: 11/069,823
- Filed: 2005-03-01
- Published: 2006-03-09
- Earliest claimed: 1998-03-23
- Inventors: Ypke van Oosterhout; Janny van Emst
- Web page: https://patentgrep.com/patent/US20060051355A1

## CPC

- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6827: {Ricin A}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides novel means and methods for treating unwanted side effects in transplantations, such as GVHD and allograft rejection. The invention provides immunotoxins comprising an antibody and a toxic substance, whereby cocktails of such conjugates are directed to different targets associated with one population of cells, wherein one target is chosen from CD3 or CD7. The preferred combination is a cocktail directed against both CD3 and CD7.

## Claims

### Claim 1

A pharmaceutical composition for eliminating or reducing the number of unwanted CD3 and/or CD7 positive cells, said pharmaceutical composition consisting of:
first molecules directed against CD3; and
second molecules, distinct from said first molecules, said second molecules targeting CD7, wherein at least one of said first and said second molecules include a toxic moiety.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein said second molecules are antibodies.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein said toxic moiety is chemically linked to said first and second molecules.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein said first and second molecules are provided with toxic moieties, wherein said toxic moieties are the same or different.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein said second molecules include a toxic moiety.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein said toxic moiety is ricin.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein said ricin is deglycosylated ricin A.

### Claim 8 (depends on 6)

The pharmaceutical composition of claim 6, wherein the toxic moiety is at least the equivalent dose of 25 micrograms of ricin A per square meter of body surface of a subject to be treated with said pharmaceutical composition.

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8, wherein the toxic moiety is at least the equivalent dose of 100 micrograms of ricin A per square meter of the subject's body surface per administration.

### Claim 10 (depends on 8)

The pharmaceutical composition of claim 8, wherein the toxic moiety is at most the equivalent dose of 25 mg of ricin A per square meter of the subject's body surface per infusion.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, wherein said first molecules are antibodies.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, wherein said second molecules are antibodies.

### Claim 13 (depends on 11)

The pharmaceutical composition of claim 11, wherein said first molecules are gamma2B IgG.

### Claim 14 (depends on 12)

The pharmaceutical composition of claim 12, wherein said toxic moiety is deglycosylated ricin A.

### Claim 15 (depends on 12)

The pharmaceutical composition of claim 12, wherein said toxic moiety is chemically linked to said first and second molecules.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, wherein both said first and second molecules are provided with toxic moieties, which may be the same or different toxic moieties.

### Claim 17

A method of treating a disease state in a subject believed to be suffering therefrom, said disease state selected from at least one of the group consisting of: Graft vs. Host disease, graft rejections, T-cell leukemias, T-cell lymphomas, other lymphomas, other CD3 and/or CD7 malignancies, autoimmune diseases, and infectious immune disease, said method comprising administering to the subject an amount of a pharmaceutical composition consisting of:
first molecules directed against a CD3 positive cell; and
second molecules, distinct from said first molecules, directed against a CD7 positive cell, wherein at least the second molecules include a toxic moiety.

### Claim 18 (depends on 17)

The method according to claim 17, wherein said second molecules specifically recognize CD7.

### Claim 19

A pharmaceutical composition for eliminating or reducing the number of unwanted CD3 and/or CD7 positive cells, said pharmaceutical composition consisting of:
anti-CD3 antibodies; and
anti-CD7 antibodies, wherein each of said anti-CD3 antibodies and said anti-CD7 antibodies include a toxic moiety.

### Claim 20

A method of treating a disease state in a subject believed to be suffering therefrom, said disease state selected from at least of the group consisting of: Graft vs. Host disease, graft rejections, T-cell leukemias, T-cell lymphomas, other lymphomas, other CD3 and/or CD7 malignancies, autoimmune diseases, and infectious immune diseases, said method comprising administering to the subject an amount of a pharmaceutical composition consisting of:
anti-CD3 antibodies; and
anti-CD7 antibodies, wherein each of said anti-CD3 antibodies and said anti-CD7 antibodies include a toxic moiety.
